Suppr超能文献

双膦酸盐类药物的使用与结直肠癌风险:系统评价和荟萃分析。

Bisphosphonate use and risk of colorectal cancer: a systematic review and meta-analysis.

机构信息

Department of Pharmacology, School of Medicine, University of Athens, Athens, Greece; Hellenic Centre for Disease Control and Prevention, Athens, Greece; Department of Computer Science and Biomedical Informatics, University of Central Greece, Lamia, Greece.

出版信息

Br J Clin Pharmacol. 2013 Sep;76(3):329-37. doi: 10.1111/bcp.12135.

Abstract

AIM

A growing body of evidence suggests that bisphosphonates may have chemopreventive potential against colorectal cancer. Our aim was to examine this association through a meta-analysis of observational studies.

METHODS

A comprehensive search for relevant articles published up to October 2012 was performed, reviews of each study were conducted and data were abstracted. Prior to meta-analysis, the studies were evaluated for publication bias and heterogeneity. Pooled relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated using the random effects and the fixed effects models. Subgroup and sensitivity analyses were also performed.

RESULTS

Eight large population-based epidemiological studies (one case-control, two nested case-control analyses within a cohort and five cohort studies), involving more than 630 000 participants, contributed to the analysis. We found no evidence of publication bias. However, significant heterogeneity was detected among the cohort studies. The analysis revealed a significant protective association between bisphosphonate use and colorectal cancer risk (fixed RR = 0.85, 95% CI 0.80, 0.90, random RR = 0.85, 95% CI 0.75, 0.96). When the analysis was stratified into subgroups according to study design, the association was inverse in both case-control and cohort studies, but only in the former was it statistically significant. The sensitivity analysis confirmed the stability of our results. Furthermore, we found evidence for a dose effect; Long term bisphosphonate use was associated with a 27% decrease in the risk of developing colorectal cancer as compared with non-use (RR = 0.73, 95% CI 0.57, 0.93).

CONCLUSION

Our findings support a protective effect of bisphosphonates against colorectal cancer. However, further evidence is warranted.

摘要

目的

越来越多的证据表明,双膦酸盐类药物可能具有预防结直肠癌的化学预防作用。我们的目的是通过对观察性研究的荟萃分析来检验这种关联。

方法

对截至 2012 年 10 月发表的相关文章进行了全面检索,对每篇研究进行了综述,并提取了数据。在进行荟萃分析之前,评估了研究的发表偏倚和异质性。使用随机效应和固定效应模型计算了合并的相对风险(RR)估计值和 95%置信区间(CI)。还进行了亚组和敏感性分析。

结果

共有 8 项大型基于人群的流行病学研究(1 项病例对照研究,2 项队列内嵌套病例对照分析和 5 项队列研究),涉及超过 630000 名参与者,对分析做出了贡献。我们没有发现发表偏倚的证据。然而,队列研究之间存在显著的异质性。分析显示,双膦酸盐类药物的使用与结直肠癌风险之间存在显著的保护关联(固定 RR=0.85,95%CI 0.80,0.90,随机 RR=0.85,95%CI 0.75,0.96)。当根据研究设计对分析进行分层时,病例对照研究和队列研究都呈负相关,但只有前者具有统计学意义。敏感性分析证实了我们的结果是稳定的。此外,我们发现了剂量效应的证据;与不使用相比,长期使用双膦酸盐类药物与结直肠癌风险降低 27%相关(RR=0.73,95%CI 0.57,0.93)。

结论

我们的研究结果支持双膦酸盐类药物对结直肠癌具有保护作用。然而,还需要进一步的证据。

相似文献

1
Bisphosphonate use and risk of colorectal cancer: a systematic review and meta-analysis.
Br J Clin Pharmacol. 2013 Sep;76(3):329-37. doi: 10.1111/bcp.12135.
2
Exposure to bisphosphonates and risk of colorectal cancer.
Br J Clin Pharmacol. 2013 Sep;76(3):320-8. doi: 10.1111/bcp.12105.
3
Bisphosphonate use and gastrointestinal tract cancer risk: meta-analysis of observational studies.
World J Gastroenterol. 2012 Oct 28;18(40):5779-88. doi: 10.3748/wjg.v18.i40.5779.
5
Oral bisphosphonates and the risk of colorectal cancer: a meta-analysis.
J Clin Gastroenterol. 2013 Oct;47(9):741-8. doi: 10.1097/MCG.0b013e31829e446b.
6
Bisphosphonates are associated with reduced risk of colorectal cancer: a systematic review and meta-analysis.
Clin Gastroenterol Hepatol. 2013 Mar;11(3):232-9.e1. doi: 10.1016/j.cgh.2012.11.026. Epub 2012 Dec 4.
9
Reduced risk of colorectal cancer with use of oral bisphosphonates: a systematic review and meta-analysis.
J Clin Oncol. 2013 Feb 10;31(5):623-30. doi: 10.1200/JCO.2012.42.9530. Epub 2012 Dec 26.
10
Bisphosphonates for breast cancer.
Cochrane Database Syst Rev. 2005 Jul 20(3):CD003474. doi: 10.1002/14651858.CD003474.pub2.

引用本文的文献

1
Cellular Carcinogenesis: Role of Polarized Macrophages in Cancer Initiation.
Cancers (Basel). 2022 Jun 6;14(11):2811. doi: 10.3390/cancers14112811.
3
Bisphosphonates and risk of cancers: a systematic review and meta-analysis.
Br J Cancer. 2020 Nov;123(10):1570-1581. doi: 10.1038/s41416-020-01043-9. Epub 2020 Sep 9.
4
Risk of colorectal cancer in users of bisphosphonates: analysis of population-based electronic health records.
Eur J Epidemiol. 2020 Jan;35(1):37-48. doi: 10.1007/s10654-019-00584-5. Epub 2019 Nov 16.
5
Oral bisphosphonates and colorectal cancer.
Sci Rep. 2017 Mar 10;7:44177. doi: 10.1038/srep44177.
7
Oral bisphosphonates and colon cancer: an update.
Ther Adv Musculoskelet Dis. 2015 Aug;7(4):160-8. doi: 10.1177/1759720X15582144.

本文引用的文献

1
A prospective study of bisphosphonate use and risk of colorectal cancer.
J Clin Oncol. 2012 Sep 10;30(26):3229-33. doi: 10.1200/JCO.2011.39.2670. Epub 2012 May 29.
4
Potential therapeutic effects of oral bisphosphonates on the intestine.
Ann N Y Acad Sci. 2011 Dec;1240:E19-25. doi: 10.1111/j.1749-6632.2011.06372.x.
5
Exposure to oral bisphosphonates and risk of cancer.
Int J Cancer. 2012 Sep 1;131(5):E717-25. doi: 10.1002/ijc.27389. Epub 2012 Jan 11.
6
Occurrence of gastrointestinal cancer in users of bisphosphonates and other antiresorptive drugs against osteoporosis.
Calcif Tissue Int. 2011 Dec;89(6):434-41. doi: 10.1007/s00223-011-9539-4. Epub 2011 Oct 16.
7
Exposure to bisphosphonates and risk of colorectal cancer: a population-based nested case-control study.
Cancer. 2012 Mar 1;118(5):1236-43. doi: 10.1002/cncr.26395. Epub 2011 Aug 5.
9
Use of bisphosphonates and reduced risk of colorectal cancer.
J Clin Oncol. 2011 Mar 20;29(9):1146-50. doi: 10.1200/JCO.2010.33.7485. Epub 2011 Feb 14.
10
Developing the evidence base for cancer chemoprevention: use of meta-analysis.
Curr Drug Targets. 2011 Dec;12(13):1989-97. doi: 10.2174/138945011798184191.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验